Transactions of Managers and Closely Associated Persons

Rhea-AI Summary

Alvotech (ALVO) disclosed filings to the Luxembourg CSSF showing a single share transfer within the Aztiq group: 2,701,617 shares were sold and acquired on January 30, 2026 at USD 4.74 per share. The notices reflect an intra‑group transfer between ATP Holdings ehf. and Aztiq Pharma Partners S.à r.l.

Contact provided: Benedikt Stefansson, VP investor relations, valvotech.ir@alvotech.com.

AI-generated analysis. How Rhea-AI works. Not financial advice.

News Market Reaction – ALVO

-4.09%

-4.09% News Effect

On the day this news was published, ALVO declined 4.09%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details an internal transfer of 2,701,617 shares at USD 4.74 per share between ent...

Analysis

This announcement details an internal transfer of 2,701,617 shares at USD 4.74 per share between entities within the Aztiq group, highlighting continued transparency around transactions by managers and closely associated persons. Because the shares moved within the same ownership group, the economic impact on outside shareholders appears limited. Investors following Alvotech may focus more on prior news about capital increases, clinical milestones, and commercialization agreements when assessing the overall equity story.

Key Figures

Shares transferred: 2,701,617 shares Transaction price: USD 4.74 per share Current share price: USD 4.09

3 metrics

Shares transferred 2,701,617 shares Intra-group transfer on January 30, 2026

Transaction price USD 4.74 per share Price for 2,701,617-share intra-group transaction

Current share price USD 4.09 Pre-news market price from context data

Historical Context

5 past events · Latest: Feb 11 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 11	Share capital increase	Negative	-6.7%	Issued 12,500,000 new shares to subsidiary to support prior obligations.
Feb 05	Clinical trial results	Positive	-2.0%	Pivotal PK study for AVT80 met all primary endpoints versus Entyvio.
Feb 02	Commercial agreements	Positive	-0.9%	Signed Sandoz supply and commercialization deals for multiple biosimilars.
Jan 29	Settlement agreement	Positive	+2.5%	Global licensing and settlement for Eylea biosimilar enabling staged launches.
Jan 07	Insider transaction correction	Neutral	+1.5%	Corrected CSSF filings for large insider-related share trades in Dec 2025.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent positive operational and clinical news has often coincided with flat-to-negative next-day moves, while technical or clarification notices saw modest positive or negative reactions.

Recent Company History

Over recent months, Alvotech has reported several strategically important events, including a global settlement for its Eylea biosimilar, new commercialization agreements, and positive pivotal PK results for AVT80, alongside capital structure moves such as a 12,500,000-share issuance on Feb 11, 2026. It also frequently reports transactions by entities closely associated with management, including large trades in December 2025. Compared with these items, the latest intra-group transfer at USD 4.74 per share primarily extends this pattern of detailed transparency around insider-related dealings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Attached are copies of two filings with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons. ATP Holdings ehf. announced a sale of 2,701,617 shares in Alvotech on January 30, 2026, and Aztiq Pharma Partners S.à r.l. ("Aztiq") announced the acquisition of 2,701,617 shares in Alvotech on January 30, 2026. ATP Holdings ehf. belongs to the Aztiq group and the transaction was thus a transfer of shares within the group. The announcements related to the same transaction and the transaction price was USD 4.74 per share.

ALVOTECH INVESTOR RELATIONS
Benedikt Stefansson, VP
alvotech.ir@alvotech.com

Attachments

• Notification - Aztiq Pharma Partners 2026-02-26
• ATP Managers' Transaction Notification 2026-02-11

FAQ

What transaction did ALVO disclose on February 26, 2026?

It disclosed a registered intra‑group transfer of 2,701,617 shares on January 30, 2026. According to the company, ATP Holdings ehf. sold and Aztiq Pharma Partners acquired the shares at USD 4.74 per share and both filings were filed with the CSSF.

Does the ALVO filing show a market sale or intra‑group transfer?

The filing shows an intra‑group transfer rather than an arms‑length market sale. According to the company, ATP Holdings belongs to the Aztiq group and the transaction represented a transfer of shares within that group on January 30, 2026.

How many ALVO shares changed hands and at what price on January 30, 2026?

A total of 2,701,617 shares were reported transferred at USD 4.74 per share. According to the company, both the sale and the acquisition were notified to the Luxembourg CSSF as related parts of the same transaction.

Which parties were involved in the ALVO managers' transaction notices?

The notices named ATP Holdings ehf. and Aztiq Pharma Partners S.à r.l. as the selling and acquiring parties. According to the company, ATP Holdings belongs to the Aztiq group, making the move an intra‑group transfer reported to the CSSF.

Where can investors direct inquiries about the ALVO transaction disclosure?

Investors can contact Benedikt Stefansson, VP investor relations, using the provided email address. According to the company, investor relations contact is valvotech.ir@alvotech.com for questions about the CSSF notifications dated February 26, 2026.